title: High-throughput measurements of the optical redox ratio using a commercial microplate reader.
abstract: There is a need for accurate, high-throughput, functional measures to gauge the efficacy of potential drugs in living cells. As an early marker of drug response in cells, cellular metabolism provides an attractive platform for high-throughput drug testing. Optical techniques can noninvasively monitor NADH and FAD, two autofluorescent metabolic coenzymes. The autofluorescent redox ratio, defined as the autofluorescence intensity of NADH divided by that of FAD, quantifies relative rates of cellular glycolysis and oxidative phosphorylation. However, current microscopy methods for redox ratio quantification are time-intensive and low-throughput, limiting their practicality in drug screening. Alternatively, high-throughput commercial microplate readers quickly measure fluorescence intensities for hundreds of wells. This study found that a commercial microplate reader can differentiate the receptor status of breast cancer cell lines (p < 0.05) based on redox ratio measurements without extrinsic contrast agents. Furthermore, microplate reader redox ratio measurements resolve response (p < 0.05) and lack of response (p > 0.05) in cell lines that are responsive and nonresponsive, respectively, to the breast cancer drug trastuzumab. These studies indicate that the microplate readers can be used to measure the redox ratio in a high-throughput manner and are sensitive enough to detect differences in cellular metabolism that are consistent with microscopy results.
authors: Taylor M
authors: TM
authors: Cannon
authors: Amy T
authors: AT
authors: Shah
authors: Alex J
authors: AJ
authors: Walsh
authors: Melissa C
authors: MC
authors: Skala
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology*; D001943:Breast Neoplasms / Q000378:metabolism*; D045744:Cell Line, Tumor; D005260:Female; D005182:Flavin-Adenine Dinucleotide / Q000032:analysis / Q000378:metabolism; D057166:High-Throughput Screening Assays / Q000295:instrumentation / Q000379:methods*; D006801:Humans; D009243:NAD / Q000032:analysis / Q000378:metabolism; D061848:Optical Imaging / Q000295:instrumentation / Q000379:methods*; D010084:Oxidation-Reduction / Q000187:drug effects*
chemical_list: D000970:Antineoplastic Agents; D009243:NAD; D005182:Flavin-Adenine Dinucleotide
references: Science. 1956 Feb 24;123(3191):309-14
references: 13298683
references: Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19494-9
references: 18042710
references: J Clin Oncol. 2002 Feb 1;20(3):719-26
references: 11821453
references: FASEB J. 2001 Apr;15(6):907-15
references: 11292650
references: Clin Cancer Res. 2005 Feb 1;11(3):971-81
references: 15709162
references: Biomed Opt Express. 2012 Jan 1;3(1):75-85
references: 22254170
references: Anal Chem. 2007 Mar 1;79(5):2137-49
references: 17269654
references: Cancer Res. 2013 Oct 15;73(20):6164-74
references: 24130112
references: Clin Cancer Res. 2009 Dec 1;15(23):7266-76
references: 19934303
references: Biophys J. 2002 May;82(5):2811-25
references: 11964266
references: Cancer Cell. 2009 May 5;15(5):429-40
references: 19411071
references: J Neurosci. 2007 Jan 31;27(5):1129-38
references: 17267568
references: Mol Cell Proteomics. 2005 Nov;4(11):1686-96
references: 16048908
references: Nat Rev Drug Discov. 2010 Mar;9(3):203-14
references: 20168317
references: Cancer Res. 2010 Jun 1;70(11):4759-66
references: 20460512
references: Clin Med Res. 2009 Jun;7(1-2):4-13
references: 19574486
references: Clin Cancer Res. 2000 Feb;6(2):616-21
references: 10690547